Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ......

52
Potential of biomedical sensors: state of the art and future perspectives Tor Inge Tønnessen The Interventional Centre Rikshospitalet

Transcript of Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ......

Page 1: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Potential of biomedical sensors: state of the art and futureperspectives

Tor Inge TønnessenThe Interventional Centre

Rikshospitalet

Page 2: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

The The oldold--timetime biosensorbiosensor

Page 3: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

The The futurefuture of of monitoringmonitoring

Page 4: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Sensors are all around us

IndustryCounting, sorting, reading, tactile

CarsMotorTire pressureCollision activate air bag

OfficeHome

Page 5: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Biosensor

A sensor used to obtain information about a life processBiosensors are devices that can detect and/or quantify molecules of interest. Sensing occurs when there is an interaction between the target molecule and a biological macromolecule (e.g. enzyme, antibody, receptor or DNA strand).

Page 6: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

What is a biosensor?What is a biosensor?

Broader definition: Sensing Broader definition: Sensing (measuring, monitoring) a functional (measuring, monitoring) a functional biological parameter in an organ or biological parameter in an organ or systemicallysystemicallyIn vitroIn vitro–– PointPoint--ofof--carecareEx vivoEx vivoIn vivoIn vivo

Page 7: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Many types og tecnnology

Electrochemical

Fiberoptic

SS S S SS S S S

FructoseDehydrogenase

OctadecylMercaptan

Gold Electrode

S S S S S S S S S S S S S S S S S S S S S S S S S

PC and PEPhospholipid

Coenzyme Q6

SSS S S SS

COO-

NH 3+

COO-

COO-

NH 3+

NH 3+

2e-

D-Fructose 5-Keto-D-Fructose

Page 8: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Time resolution

One time shot

Repeated measurements

Continous, real-time

Page 9: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

The evolution of glucose sensors

Page 10: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Some defining events in the history of commercial biosensor development

Abbott acquires TheraSense for $1.2 billion2004

i-STAT acquired by Abbott for $392 million2003

LifeScan purchases Inverness Medical's glucose testing business for $1.3 billion2001

Merger of Roche and Boehringer Mannheim to form Roche Diagnostics1998

Launch of LifeScan FastTake blood glucose biosensor1998

Abbott acquires MediSense for $867 million1996

Glucocard launched1996

i-STAT launches hand-held blood analyser1992

Launch of the MediSense ExacTech blood glucose biosensor1987

First mediated amperometric glucose biosensor: ferrocene used with glucose oxidase for the detection of glucose (Cass et al., 1984)1984

First fibre optic-based biosensor for glucose (Schultz, 1982)1982

Miles Biostator: first bedside artificial pancreas1976

First commercial biosensor: Yellow Springs Instruments glucose biosensor1973–1975

First description of a biosensor: an amperometric enzyme electrode for glucose (Clark and Lyons, 1962)1962

Invention of the oxygen electrode (Clark, 1956)1956

First glass pH electrode1922

First report on the immobilisation of proteins: adsorption of invertase on activated charcoal1916

EventDate

Page 11: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Our vision

BSD is dedicated to improving human safety and well-being through innovative, fast-working, cost effective and reliable disposable sensors for the medical, food, security, environmental and other diagnostic communities. It is envisioned that BSD sensors will be widely used in slaughterhouses, factories, hospitals, and doctor’s offices worldwide, with some applications extensively employed in homes and on battlefields throughout the world.

Page 12: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Biosensors agains terrorism

- The Bush White House has endorsed a $3.25 billion Senate bill to beef up the United States' ability to detect and respond to biological and chemical attacks.

Page 13: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Biosensors against obesity

Page 14: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

THE CANARY SINGS AGAINTHE CANARY SINGS AGAIN

Page 15: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion
Page 16: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

EarlyEarly warningwarning

Page 17: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

The everyday problem..The everyday problem..

Page 18: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

We obtain the global We obtain the global parametersparameters

but we do not but we do not know what know what happens in the happens in the organorgan

Page 19: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Injury to most organs are Injury to most organs are detected too latedetected too late

Except for EKG, we do not have realExcept for EKG, we do not have real--time detection of organ injurytime detection of organ injuryMost organs reveal symptoms lateMost organs reveal symptoms lateIn the anesthetized patient and the In the anesthetized patient and the ICU patients, symptoms are absentICU patients, symptoms are absentReliable biosensors are badly neededReliable biosensors are badly needed

Page 20: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Placement of a sensorPlacement of a sensor

Page 21: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Why use a biosensor?

Early detection imply better prognosisContinuous measurements enable us to titrate treatment according to responseDiseases may be treated even before symptoms occur

Page 22: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

IschemiaMost prevalent cause of mortality and morbidity in the Western world (myocardial infarction, stroke, trauma)If ischemia is detected early it is most often reversibleExcept from EKG, there is no clinical method available for real-time monitoring of ischemiaIndirect methods (enzyme analysis etc) are often unspecific and slow

Page 23: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

The diagnosis of ischemia is often retrospective

We diagnose that the injury has occurred-but it is too late because the injury has become irreversible

Page 24: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

How do the cells try to survive without oxygen?

Reduce ”luxury metabolism” (O2 conformity)KidneyHeart

Deplete the storage of energy rich substancesSkeletal muscleLiver

Convert to anaerobic metabolism

Page 25: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

AnaerobicmetabolismDesperate attempt to survive until oxygen reappearsSecure a small energy productionSide effect: Acidification of the cells

Glucose

Pyruvate Lactate

NADH

H O

O

CO

NADNADH

ATPG

lycol

ysis

Kreb

scy

cle

Elec

tron

trans

port

2

2

2

+

Page 26: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Intracellular acidosis

H+Proteins

Phosphate

HCO3-

CO2

Page 27: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

CO2 productionOxidative phosphorylation

Large productionRapid elimination by perfusing blood

Anaerobic metabolismLess CO2 produced, but it is not transported away due to lack of blood supply, and will accumulate in the organ H+ + HCO3

- ⇒ CO2

Glucose

Pyruvate Lactate

NADH

H O

O

CO

NADNADH

ATP

Glyc

olys

isKr

ebs

cycl

eEl

ectro

ntra

nspo

rt

2

2

2

+

Page 28: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

PCO2 during progressive flow reduction

Oxygen delivery, DO2 (ml/kg/min)0 10 20 30 40 50

PC

O2,

liver

sur

face

(Tor

r)

50

100

150

200

250

Oxy

gen

upta

ke, V

O2 (

ml/k

g/m

in)

0

2

4

6

8

10*

*

*

*

**

*

*A

Page 29: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Monitoring of organ metabolism

Page 30: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Monitoring of organ metabolism

Page 31: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Principle of microdialysis

Page 32: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Mikrodialyse (CMA 600)

Page 33: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Microdialysis

Page 34: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Looking closer…

Page 35: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Ischemia in microsurgical free flap

Page 36: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Neurotrend

pH

PCO2

PO2

Temperatur

Page 37: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Neurotrendkateter

• Diameter 0,5 mm• Membranlengde < 2,5 cm• Må beskyttes mot lys• Trykkfølsomt

Page 38: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Monitoring of organ metabolism

Page 39: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Monitoring of organ metabolism

Page 40: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

DIEP-lapp(Deep inferior epigastric perforans)

• Fri lapp.• Hud og fettvev med tilhørende blodkar hentes

fra nedre del av abdomen. • Små kar anastomoseres.• Den hyppigste komplikasjonen er svikt i

blodforsyningen.• Klinisk vurdering kan være vanskelig og

sviktende blodforsyning kan oppdages sent.

Page 41: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Venøs insuff.pCO2 pO2 DIEP 12 (sone 3): Laktat/pyruvat Reoperasjon

30.04.2002 01.05.2002 02.05.2002 03.05.2002 04.05.200200:00 00:00 00:00 00:00

0

5

10

15

0

20

40

60

80

L/P-ratiopCO2pO2

Reopr.

Page 42: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

First prototype 3-axis accelerometer sensor

Page 43: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Heart Motion

• Heart motion measurements– Good precision– 3 axes: Full 3D motion pattern

• Motion abnormalities seen– Arrhythmias, fibrillation, influence

• More subtle changes: More sophisticated signal analysis needed– Ischemia seen as changes in frequency plots

Arrhythmia

Page 44: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Frequency distribution in 2 sec time windows before and after occlusion

Frequency footprintBefore occlusion

Frequency footprintAfter occlusion

Page 45: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Frequency Analysis. Spectrogram

LAD Occlusion

-Analysis of periodic signals-Sensitive to small changes-Ischemia changes pattern

Frequency [1/min]

Page 46: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Cooperation with WL Gore

Page 47: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

IscAlert

Page 48: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

WhyWhy diddid so so fewfew succedsucced??

Page 49: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Brain drainBrain drain

Page 50: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Are Are wewe sleeping in an era of sleeping in an era of new new inventionsinventions??

Page 51: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

TryingTrying againagain and and againagain

Come on! It can‘t go

wrong every time...

Page 52: Potential of biomedical sensosr- Tønnessen - SINTEF · Potential of biomedical sensors: ... macromolecule (e.g. enzyme, antibody, ... 2004 Abbott acquires TheraSense for $1.2 billion

Not Not everyevery presentationpresentation isissuccessfulsuccessful